Yakang Biotech announced that the company initially invested 70 million yuan in Jiangxi Zhonghong, and the two sides are currently negotiating, and the company plans to partially withdraw from the investment through targeted capital cuts. Jiangxi Zhonghong agreed to return the 10 million yuan capital reduction amount and pay compensation for the use of the corresponding funds. The company's shareholding ratio will drop from 22.8261% to 20.2247%; if Suzhou Jikang and Suzhou Guofa withdraw 15 million yuan at the same time, the company's shareholding ratio will drop to 20.9302%. This transaction constitutes a related transaction, does not constitute a major asset restructuring, and all parties are still required to complete the review process. In the past 12 months, the two sides have accumulated 1.6811 million yuan in related transactions.

Yakang Biotech announced that the company initially invested 70 million yuan in Jiangxi Zhonghong, and the two sides are currently negotiating, and the company plans to partially withdraw from the investment through targeted capital cuts. Jiangxi Zhonghong agreed to return the 10 million yuan capital reduction amount and pay compensation for the use of the corresponding funds. The company's shareholding ratio will drop from 22.8261% to 20.2247%; if Suzhou Jikang and Suzhou Guofa withdraw 15 million yuan at the same time, the company's shareholding ratio will drop to 20.9302%. This transaction constitutes a related transaction, does not constitute a major asset restructuring, and all parties are still required to complete the review process. In the past 12 months, the two sides have accumulated 1.6811 million yuan in related transactions.